On cross-ratio distortion and Schwarz derivative

We prove asymptotic estimates for the cross-ratio distortion with respect to a smooth or holomorphic function in terms of its Schwarz derivative.Comment: the spelling of the name `Schwarz' correcte

Asymptotic expansions for eigenvalues and eigenfunctions of elliptic boundary-value problems with rapidly oscillating coefficients

In the paper I solve the problem of a multiple spectrum without any artificial conditions imposed and obtain whole asymptotic expansions for eigenvalues and eigen-functions of the general smooth boundary-value problem for an elliptic operator with non-uniformly oscillating coe±cients (whose homogenization is made in [7])

Herman's Theory Revisited

We prove that a $C^{2+\alpha}$-smooth orientation-preserving circle diffeomorphism with rotation number in Diophantine class $D_\delta$, $0<\delta<\alpha\le1$, is $C^{1+\alpha-\delta}$-smoothly conjugate to a rigid rotation. We also derive the most precise version of Denjoy's inequality for such diffeomorphisms.Comment: 10 page

Introduction: moving beyond chemotherapy

Epithelial ovarian cancer and related cancers arising in extrauterine Mullerian epithelium are generally chemosensitive—particularly to the platinum drugs, cisplatin and carboplatin, that form the backbone of first-line treatments upon diagnosis even at early stages. Doublets of platinums with paclitaxel have represented the standard-of-care since the late 1990s, with further notable advances taking place by intraperitoneal administration (in Gynecologic Oncology Group studies) after optimal surgical cytoreduction is achieved, and by divided doses of paclitaxel (in a Japanese GOG study). Adding another agent to improve on these results has otherwise proven to be quite challenging. Nevertheless, continued forays into introducing ‘targeted therapies’ are beginning to bear fruit, and form part of this Translational Cancer Research ( TCR ) supplement. The purpose of this supplement is to provide a summary of the advances in tumor biology and a glimpse into where targeted therapeutics are moving, and their successes to date

Integrating targeted drugs with taxanes and platinums: opportunities and challenges

In ovarian cancer, multiple attempts to adjust the standard taxane/platinum doublet by adding cytotoxic therapy or varying scheduling, dosage, and delivery have been met with limited success. Alternative methods to improve the grim prognosis of ovarian cancer, including molecular therapies, are currently under investigation. Efforts have been made to study tyrosine kinase inhibitors (including imatinib and pazopanib), Src kinase inhibitors and histone deacetylase inhibitors (HDACi) in combination with taxanes/platinums in order to improve efficacy. Unfortunately, while many pre-clinical and early phase clinical trials argue that the utilization of these molecular targets may enhance survival, only modest benefit has been seen in larger clinical trials. Other agents that have been evaluated include proteasome inhibitors, folate receptor antagonists, MEK inhibitors and opiate antagonists. In this review, we discuss the mechanisms of these targeted therapies and highlight the current and ongoing clinical trials that utilize these targeted agents in combination with taxanes and platinums in advanced ovarian cancer